Patents by Inventor Rongqun GUO

Rongqun GUO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pluripotent stem cell and T cell differentiated therefrom and application thereof
    Patent number: 11299709
    Abstract: The present invention provides a pluripotent stem cell comprising a co-expression vector in which Runx1 and Hoxa9 are of in tandem, and a T cell differentiated therefrom and application thereof. In the present invention, Pluripotent stem cells inducibly co-expressing exogenous Runx1 and Hoxa9 are successfully established by introducing an exogenous vector co-expressing Runx1 and Hoxa9 into pluripotent stem cells. The pluripotent stem cells are directionally differentiated into T-lineage progenitor cells and will be developed into T cells. The pluripotent stem cell-derived T cells obtained by the method of the present invention are not only functionally normal but also have no tumorigenic risk.
    Type: Grant
    Filed: January 11, 2018
    Date of Patent: April 12, 2022
    Assignee: GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH CHINESE ACADEMY OF SCIENCES
    Inventors: Jinyong Wang, Rongqun Guo, Mengyun Zhang, Lijuan Liu, Xiaofei Liu, Cui Lv, Juan Du
  • PLURIPOTENT STEM CELL AND T CELL DIFFERENTIATED THEREFROM AND APPLICATION THEREOF
    Publication number: 20210238548
    Abstract: The present invention provides a pluripotent stem cell comprising a co-expression vector in which Runx1 and Hoxa9 are of in tandem, and a T cell differentiated therefrom and application thereof. In the present invention, Pluripotent stem cells inducibly co-expressing exogenous Runx1 and Hoxa9 are successfully established by introducing an exogenous vector co-expressing Runx1 and Hoxa9 into pluripotent stem cells. The pluripotent stem cells are directionally differentiated into T-lineage progenitor cells and will be developed into T cells. The pluripotent stem cell-derived T cells obtained by the method of the present invention are not only functionally normal but also have no tumorigenic risk.
    Type: Application
    Filed: January 11, 2018
    Publication date: August 5, 2021
    Inventors: Jinyong WANG, Rongqun GUO, Mengyun ZHANG, Lijuan LIU, Xiaofei LIU, Cui LV, Juan DU
  • PLURIPOTENT STEM CELL AND T CELL DIFFERENTIATED THEREFROM AND APPLICATION THEREOF
    Publication number: 20200208107
    Abstract: The present invention provides a pluripotent stein cell comprising a co-expression vector in which Runx1 and Hoxa9 are of in tandem, and a T cell differentiated therefrom and application thereof. In the present invention, Pluripotent stein cells inducibly co-expressing exogenous Runx1 and Hoxa9 are successfully established by introducing an exogenous vector co-expressing Runx1 and Hoxa9 into pluripotent stein cells. The pluripotent stein cells are directionally differentiated into T-lineage progenitor cells and will be developed into T cells. The pluripotent stein cell-derived T cells obtained by the method of the present invention are not only functionally normal but also have no tumorigenic risk.
    Type: Application
    Filed: January 11, 2018
    Publication date: July 2, 2020
    Inventors: Jinyong WANG, Rongqun GUO, Mengyun ZHANG, Lijuan LIU, Xiaofei LIU, Cui LV, Juan DU